Alcohol intake and mortality among women with invasive breast cancer
British Journal of Cancer,  Clinical Article

H R Harris et al. –These findings suggest that alcohol intake up to approximately one small drink per day does not negatively impact breast cancer–specific survival and a half drink per day is associated with a decreased risk of mortality from other causes.

Methods

  • Investigated whether alcohol intake was associated with survival among 3146 women diagnosed with invasive breast cancer in the Swedish Mammography Cohort
  • Alcohol consumption was estimated using food frequency questionnaire
  • Cox proportional hazard models were used to calculate HRs and 95% CIs

Results

  • From 1987 to 2008 there were 385 breast cancer–specific deaths and 860 total deaths
  • No significant association was observed between alcohol intake and breast cancer–specific survival
  • Women who consumed 10?g per day (corresponding to approximately 0.75 to 1 drinks) or more of alcohol had an adjusted HR (95% CI) of breast cancer–specific death of 1.36 (0.82–2.26;ptrend=0.47) compared with non–drinkers
  • Significant inverse association was observed between alcohol and non–breast cancer deaths
  • Those who consumed 3.4–9.9?g per day of alcohol had a 33% lower risk of death compared with non–drinkers (95% CI 0.50–0.90;ptrend=0.04)

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Annals of Oncology, November 21, 2014    Clinical Article

2 Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: Updated results from the phase III HannaH study Annals of Oncology, November 24, 2014    Clinical Article

3 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 30, 2014    Clinical Article

4 Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: A meta-analysis Clinical Cancer Research, November 17, 2014    Evidence Based Medicine

5 Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the Randomized SweDCIS Trial Journal of Clinical Oncology, October 17, 2014    Clinical Article

6 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 23, 2014    Clinical Article

7 Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study The Breast, October 2, 2014    Clinical Article

8 Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS) The Breast, November 13, 2014    Clinical Article

9 Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer: A trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology, November 26, 2014    Clinical Article

10 Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer Journal of Clinical Oncology, November 4, 2014    Clinical Article

11 Triple negative breast cancer - BCL2 in prognosis and prediction Current Drug Targets, November 10, 2014    Clinical Article

12 Inflammatory breast cancer: An overview Critical Reviews in Oncology/Hematology, November 20, 2014    Review Article

13 Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer Full Text Breast Cancer: Targets and Therapy, November 21, 2014    Free full text    Clinical Article

14 The risk of breast cancer associated with specific patterns of migraine history Cancer Causes and Control, November 21, 2014    Clinical Article

15 Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score Journal of Clinical Oncology, October 27, 2014    Clinical Article

16 Changing in the pattern of breast cancer burden among African American women: Evidence based on 29 states and District of Columbia during 1998 to 2010 Annals of Epidemiology , November 14, 2014    Clinical Article

17 Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer Annals of Oncology, November 4, 2014    Clinical Article

18 'Knowledge is power': Perceived needs and preferred services of male partners of women newly diagnosed with breast cancer Supportive Care in Cancer, November 26, 2014    Clinical Article

19 Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial The Lancet Oncology, November 3, 2014    Clinical Article

20 Complementary and alternative medicine use by breast cancer patients at time of surgery which increases the potential for excessive bleeding Integrative Cancer Therapies , November 20, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore